RS61611B1 - Upotreba kompozicije koja sadrži benzoat kod poremećaja ciklusa uree i neurodegenerativnih poremećaja - Google Patents
Upotreba kompozicije koja sadrži benzoat kod poremećaja ciklusa uree i neurodegenerativnih poremećajaInfo
- Publication number
- RS61611B1 RS61611B1 RS20210230A RSP20210230A RS61611B1 RS 61611 B1 RS61611 B1 RS 61611B1 RS 20210230 A RS20210230 A RS 20210230A RS P20210230 A RSP20210230 A RS P20210230A RS 61611 B1 RS61611 B1 RS 61611B1
- Authority
- RS
- Serbia
- Prior art keywords
- mice
- gtb
- eae
- pharmaceutical composition
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461928622P | 2014-01-17 | 2014-01-17 | |
| EP15737329.1A EP3094616B1 (en) | 2014-01-17 | 2015-01-16 | The use of glyceryl tribenzoate containing composition in neurodegenerative disorders |
| PCT/US2015/011798 WO2015109215A1 (en) | 2014-01-17 | 2015-01-16 | The use of a benzoate containing composition in urea cycle disorders and neurodegenerativre disordrs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61611B1 true RS61611B1 (sr) | 2021-04-29 |
Family
ID=53543490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210230A RS61611B1 (sr) | 2014-01-17 | 2015-01-16 | Upotreba kompozicije koja sadrži benzoat kod poremećaja ciklusa uree i neurodegenerativnih poremećaja |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9968582B2 (https=) |
| EP (1) | EP3094616B1 (https=) |
| JP (2) | JP6836905B2 (https=) |
| CA (1) | CA2936548C (https=) |
| CY (1) | CY1124115T1 (https=) |
| DK (1) | DK3094616T3 (https=) |
| ES (1) | ES2853974T3 (https=) |
| HR (1) | HRP20210361T1 (https=) |
| HU (1) | HUE053671T2 (https=) |
| LT (1) | LT3094616T (https=) |
| PL (1) | PL3094616T3 (https=) |
| PT (1) | PT3094616T (https=) |
| RS (1) | RS61611B1 (https=) |
| SI (1) | SI3094616T1 (https=) |
| SM (1) | SMT202100074T1 (https=) |
| WO (1) | WO2015109215A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202090666A1 (ru) * | 2017-10-06 | 2020-08-05 | Раш Юниверсити Медикал Сентер | Применение содержащей бензоат композиции для лечения глициновой энцефалопатии |
| JP7034314B2 (ja) * | 2017-11-22 | 2022-03-11 | 潔欣 林 | うつ病を予防または治療するための安息香酸またはその塩および誘導体 |
| US12478598B2 (en) | 2019-02-25 | 2025-11-25 | Rush University Medical Center | Compositions including cinnamic acid and methods of use thereof |
| CN114502154A (zh) * | 2019-07-16 | 2022-05-13 | 拉什大学医学中心 | 含苯甲酸酯的组合物治疗神经退行性疾病的用途 |
| CN116390761A (zh) * | 2020-10-28 | 2023-07-04 | 拉什大学医学中心 | 肉桂酸苄酯组合物在治疗甘氨酸脑病和尿素循环障碍中的应用 |
| CA3205005A1 (en) * | 2020-12-16 | 2022-06-23 | Rush University Medical Center | Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders |
| JP2025503457A (ja) * | 2021-12-16 | 2025-02-04 | ザ ユナイテッド ステイツ ガバメント アズ リプレゼンティド バイ ザ デパートメント オブ ヴェテランズ アフェアーズ | 神経系損傷及び障害の治療のための安息香酸塩 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) * | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| WO2008083226A2 (en) | 2006-12-28 | 2008-07-10 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
-
2015
- 2015-01-16 WO PCT/US2015/011798 patent/WO2015109215A1/en not_active Ceased
- 2015-01-16 CA CA2936548A patent/CA2936548C/en active Active
- 2015-01-16 PL PL15737329T patent/PL3094616T3/pl unknown
- 2015-01-16 DK DK15737329.1T patent/DK3094616T3/da active
- 2015-01-16 US US15/110,702 patent/US9968582B2/en active Active
- 2015-01-16 HR HRP20210361TT patent/HRP20210361T1/hr unknown
- 2015-01-16 SI SI201531511T patent/SI3094616T1/sl unknown
- 2015-01-16 EP EP15737329.1A patent/EP3094616B1/en active Active
- 2015-01-16 RS RS20210230A patent/RS61611B1/sr unknown
- 2015-01-16 SM SM20210074T patent/SMT202100074T1/it unknown
- 2015-01-16 ES ES15737329T patent/ES2853974T3/es active Active
- 2015-01-16 JP JP2016565117A patent/JP6836905B2/ja active Active
- 2015-01-16 PT PT157373291T patent/PT3094616T/pt unknown
- 2015-01-16 HU HUE15737329A patent/HUE053671T2/hu unknown
- 2015-01-16 LT LTEP15737329.1T patent/LT3094616T/lt unknown
-
2019
- 2019-10-18 JP JP2019191224A patent/JP2020037558A/ja active Pending
-
2021
- 2021-03-09 CY CY20211100204T patent/CY1124115T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1124115T1 (el) | 2022-05-27 |
| EP3094616B1 (en) | 2020-12-23 |
| US9968582B2 (en) | 2018-05-15 |
| ES2853974T3 (es) | 2021-09-20 |
| SI3094616T1 (sl) | 2021-07-30 |
| JP2017505811A (ja) | 2017-02-23 |
| SMT202100074T1 (it) | 2021-05-07 |
| CA2936548A1 (en) | 2015-07-23 |
| US20160331714A1 (en) | 2016-11-17 |
| EP3094616A1 (en) | 2016-11-23 |
| HRP20210361T1 (hr) | 2021-04-16 |
| CA2936548C (en) | 2022-08-30 |
| JP2020037558A (ja) | 2020-03-12 |
| HUE053671T2 (hu) | 2021-07-28 |
| LT3094616T (lt) | 2021-04-12 |
| PL3094616T3 (pl) | 2021-05-31 |
| WO2015109215A1 (en) | 2015-07-23 |
| JP6836905B2 (ja) | 2021-03-03 |
| EP3094616A4 (en) | 2017-08-23 |
| PT3094616T (pt) | 2021-03-03 |
| DK3094616T3 (da) | 2021-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cummings et al. | Alzheimer’s disease: novel targets and investigational drugs for disease modification | |
| RS61611B1 (sr) | Upotreba kompozicije koja sadrži benzoat kod poremećaja ciklusa uree i neurodegenerativnih poremećaja | |
| JP5712207B2 (ja) | 脳疾患及び状態の予防及び治療のための組成物及び方法 | |
| CA3041165A1 (fr) | Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus | |
| AU2014260468A1 (en) | Sobetirome in the treatment of myelination diseases | |
| US20120237482A1 (en) | Methods for treatment of neurological disorders by modulation of microglial activation | |
| RU2336870C2 (ru) | Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта | |
| US11207331B2 (en) | Agents, compositions and methods for enhancing neurological function | |
| JP2020502278A (ja) | 青黛抽出物又はその分画物を有効成分として含む炎症性腸疾患の予防又は治療のための医薬組成物 | |
| AU2022200277A1 (en) | The use of a benzoate containing composition to treat glycine encephalopathy | |
| JP2022521233A (ja) | 桂皮酸を含む組成物及びその使用方法 | |
| CN106794189A (zh) | 阿尔茨海默疾病或痴呆预防、治疗或拖延用药学组合物 | |
| CN108210818B (zh) | 一种防治神经退行性疾病的药物组合物及其制备方法和用途 | |
| Bachert et al. | Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis | |
| CN106361738A (zh) | 治疗、预防脑白质损伤的医药组合物及其医药用途 | |
| CN116390761A (zh) | 肉桂酸苄酯组合物在治疗甘氨酸脑病和尿素循环障碍中的应用 | |
| WO2005002568A1 (fr) | Utilisation de 1-n-butylphtalide pour la prevention ou les traitements de la demence | |
| CN104411308B (zh) | 通过给予某些合成化合物治疗阿尔茨海默病的方法 | |
| CN115429799A (zh) | Magl抑制剂在制备预防或治疗肝炎药物中的用途 | |
| CN104173361A (zh) | 宝霍苷i在制备防治阿尔茨海默病药物中的用途 | |
| CN114984017A (zh) | 用于中枢神经系统脱髓鞘疾病治疗的化合物 | |
| JP5634062B2 (ja) | 脳機能改善用組成物および脳機能を改善する方法 | |
| US20230201134A1 (en) | Compositions for the management of demyelinating disorders | |
| CN113057977A (zh) | 一种改善学习记忆的片剂及其制备方法 | |
| HK40015331B (en) | Brain function-improving agent, food, and medicine using lipopolysaccharide |